, Institut National du Cancer. Les cancers en France, 2017.

S. R. Lakhani, I. O. Ellis, S. J. Schnitt, P. H. Tan, and M. J. Van-der-vijver, World Health Organization Classification of Tumours of the breast. World Heal Organ Classif tumours, Organ. Classif. tumours, p.240, 2012.

F. Penault-llorca, Évolution de la classification des cancers du sein, Biol Aujourdhui, vol.208, issue.4, pp.251-260, 2014.

Q. Xiong, V. Valero, V. Kau, S. Kau, S. Taylor et al., Female patients with breast carcinoma age 30 years and younger have a poor prognosis, Cancer Interdiscip Int J Am Cancer Soc, vol.92, issue.10, pp.2523-2531, 2001.

A. Sidoni, A. Cavaliere, G. Bellezza, M. Scheibel, and E. Bucciarelli, Breast cancer in young women: clinicopathological features and biological specificity, Breast, vol.12, issue.4, pp.247-50, 2003.

K. Zabicki, J. A. Colbert, F. J. Dominguez, M. A. Gadd, K. S. Hughes et al., Breast cancer diagnosis in women? 40 versus 50 to 60 years: increasing size and stage disparity compared with older women over time, Ann Surg Oncol, vol.13, issue.8, pp.1072-1079, 2006.

C. L. Carter, C. Allen, and D. E. Henson, Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases, Cancer, vol.63, issue.1, pp.181-188, 1989.

J. S. Michaelson, M. Silverstein, D. Sgroi, J. A. Cheongsiatmoy, A. Taghian et al., The effect of tumor size and lymph node status on breast carcinoma lethality, Cancer Interdiscip Int J Am Cancer Soc, vol.98, issue.10, pp.2133-2176, 2003.

V. Vinh-hung, T. Burzykowski, G. Cserni, M. Voordeckers, J. Van-de-steene et al., Functional form of the effect of the numbers of axillary nodes on survival in early breast cancer, Int J Oncol, vol.22, issue.3, pp.697-704, 2003.

T. Saphner, D. C. Tormey, and R. Gray, Annual hazard rates of recurrence for breast cancer after primary therapy, J Clin Oncol, vol.14, issue.10, pp.2738-2784, 1996.

. O'shaughnessy, J. Extending Survival with Chemotherapy in Metastatic Breast Cancer. Oncologist, vol.10, issue.suppl_3, pp.20-29, 2005.

M. Colleoni, Z. Sun, K. N. Price, P. Karlsson, J. F. Forbes et al., Annual hazard rates of recurrence for breast cancer during 24 years of followup: results from the international breast cancer study group trials I to V, J Clin Oncol, vol.34, issue.9, p.927, 2016.

D. J. Press, M. E. Miller, E. Liederbach, K. Yao, and D. Huo, De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype

, Clin Exp Metastasis, vol.34, issue.8, pp.457-65, 2017.

H. Kennecke, R. Yerushalmi, R. Woods, M. Cheang, D. Voduc et al., Metastatic behavior of breast cancer subtypes, J Clin Oncol, vol.28, issue.20, pp.3271-3278, 2010.

C. E. Desantis, C. C. Lin, A. B. Mariotto, R. L. Siegel, K. D. Stein et al., Cancer treatment and survivorship statistics, CA Cancer J Clin, vol.64, issue.4, pp.252-71, 2014.

N. Harbeck and M. Gnant, Breast cancer. Lancet, vol.6736, issue.16, pp.1134-50, 2016.

A. E. Giuliano, J. L. Connolly, S. B. Edge, E. A. Mittendorf, H. S. Rugo et al., Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, A Cancer J Clin, vol.67, issue.4, pp.290-303, 2017.

L. Doussal, V. Tubiana-hulin, M. Friedman, S. Hacene, K. Spyratos et al., Prognostic value of histologic grade nuclear components of

(. Richardson and . Sbr, An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas, Cancer, vol.64, issue.9, pp.1914-1935, 1989.

C. Genestie, B. Zafrani, B. Asselain, A. Fourquet, S. Rozan et al., Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems

, Anticancer Res, vol.18, issue.1B, pp.571-577, 1998.

M. Hammond, D. F. Hayes, M. Dowsett, D. C. Allred, K. L. Hagerty et al., American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, J Clin Oncol, vol.28, issue.16, pp.2784-95, 2010.

B. C. Calhoun and L. C. Collins, Predictive markers in breast cancer: An update on ER and HER2 testing and reporting, Semin Diagn Pathol, vol.32, issue.5, pp.362-371, 2015.

C. A. Parise, K. R. Bauer, M. M. Brown, and V. Caggiano, Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, Breast J, vol.15, issue.6, pp.593-602, 1999.

Y. Yarden and M. Sliwkowski, Untangling the ErbB signalling network, Nat Rev Mol cell Biol, vol.2, issue.2, p.127, 2001.

E. A. Rakha and A. R. Green, Molecular classification of breast cancer: what the pathologist needs to know, Pathology, vol.49, issue.2, pp.111-120, 2017.

D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (80-), vol.235, pp.177-82, 1987.

J. Li, Z. Chen, K. Su, and J. Zeng, Clinicopathological classification and traditional prognostic indicators of breast cancer, Int J Clin Exp Pathol, vol.8, issue.7, pp.8500-8505, 2015.

E. H. Romond, E. A. Perez, J. Bryant, V. J. Suman, C. E. Geyer et al., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, vol.353, issue.16, pp.1673-1684, 2005.

S. E. Pinder, I. O. Ellis, M. Galea, S. O'rouke, R. W. Blamey et al., Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up

, Histopathology, vol.24, issue.1, pp.41-48, 1994.

P. J. Lamy, G. Romieu, and W. Jacot, uPA/PAI-1: Un outil d'individualisation de la prise en charge des cancers du sein. Biologie, implications cliniques et méthodes de dosage, Bull Cancer, vol.97, issue.3, pp.341-349, 2010.

T. Sorlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci, vol.98, pp.10869-10874, 2001.

, Faculté de médecine d'Angers. (page consultée le 01/09/19). Laboratoire d'hématologie du CHU d'Angers

B. Brahmbhatt, B. Parikh, and M. Shah, Bone marrow involvement by metastatic solid tumors, Gujarat Med J, vol.69, issue.2, pp.54-61, 2014.

H. Kopp, K. Krauss, T. Fehm, A. Staebler, J. Zahm et al., Symptomatic Bone Marrow Involvement in Breast Cancer -Clinical Presentation, Treatment, and Prognosis : A Single Institution Review of 22 Cases, Anticancer Res, vol.31, issue.11, pp.4025-4055, 2011.

G. Wiedswang, E. Borgen, R. Karesen, G. Kvalheim, J. M. Nesland et al., Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer, J Clin Oncol, vol.21, issue.18, pp.3469-78, 2003.

Y. Hung, W. Chou, T. Chen, T. Chen, P. Wang et al.,

, Prognostic Factors in Adult Patients with Solid Cancers and Bone Marrow Metastases, Asian Pacific J Cancer Prev, vol.15, issue.1, pp.61-68, 2014.

S. Braun, F. D. Vogl, B. Naume, W. Janni, M. P. Osborne et al., A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer, N Engl J Med, vol.353, pp.793-802, 2005.

A. Dufresne and X. Pivot, Traitement du cancer du sein métastatique. Le cancer du sein, pp.209-234, 2007.

M. Volkova and R. Russell, Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment, Curr Cardiol Rev, vol.7, issue.4, pp.214-234, 2011.

S. Jones, E. Erban, J. Overmoyer, B. Budd, G. T. Hutchins et al., Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer, J Clin Oncol, vol.23, issue.24, pp.5542-5551, 2005.

W. J. Gradishar, Taxanes for the treatment of metastatic breast cancer, Breast Cancer Basic Clin Res, vol.6, issue.1, pp.159-71, 2012.

B. Dávalos-félix, A. De-león-cruz, G. González-vela-j-luis, F. Juan, F. -. Noriega et al., Weekly Paclitaxel for Metastatic Breast Cancer in Patients Previously Exposed to Paclitaxel, J Cancerol, vol.2, pp.75-84, 2015.

P. Kellokumpu-lehtinen, T. Tuunanen, R. Asola, L. Elomaa, M. Heikkinen et al., Weekly paclitaxel-An effective treatment for advanced breast cancer

, Anticancer Res, vol.33, issue.6, pp.2623-2631, 2013.

F. Penault-llorca, A. Vincent-salomon, J. P. Bellocq, M. C. Matthieu, G. M. Grogan et al., Update of the GEFPICS'recommendations for HER2 status determination in breast cancers in France, Ann Pathol, vol.30, issue.5, pp.357-73, 2010.

A. E. Balaton, L. Doussal, V. Arnould, L. Barlier, C. Bellocq et al., Recommandations pour l'évaluation immunohistochimique des récepteurs hormonaux sur coupes en paraffine dans les carcinomes mammaires Mise à jour 1999, Ann Pathol, 1999.

, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE).v.5.0. Natl Institutes Heal Natl Cancer Institute, vol.46

S. Kilickap, M. Erman, M. Dinçer, S. Aksoy, K. Harputluoglu et al., Bone marrow metastasis of solid tumors : Clinicopathological evaluation of 73 cases

, Turkish J Cancer, vol.37, issue.3, pp.85-93, 2007.

B. Chernow and S. F. Wallner, Variables predictive of bone marrow metastasis, Cancer, vol.42, issue.5, pp.2373-2381, 1978.

L. Demir, M. Akyol, S. Bener, K. B. Payzin, C. Erten et al., Prognostic Evaluation of Breast Cancer Patients with Evident Bone Marrow Metastasis, Breast J, vol.20, issue.3, pp.279-87, 2014.

G. Kaur, S. Basu, P. Kaur, and T. Sood, Metastatic Bone Marrow Tumors: Study of Nine Cases and Review of the Literature, J Blood Disord Transfus, vol.02, issue.110, p.2, 2011.

T. Oskarsson, E. Batlle, and J. Massagué, Metastatic stem cells: sources, niches, and vital pathways, Cell Stem Cell, vol.14, issue.3, pp.306-327, 2014.

X. Zhang, M. Giuliano, M. Trivedi, R. Schiff, and C. K. Osborne, Metastasis Dormancy in Estrogen Receptor -Positive Breast Cancer, Clin Cancer Res, vol.19, issue.23, pp.6389-97, 2013.

G. Ren, M. Esposito, and Y. Kang, Bone metastasis and the metastatic niche, J Mol Med, vol.93, issue.11, pp.1203-1215, 2015.

R. E. Coleman, Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity, Clin Cancer Res, vol.12, issue.20, pp.6243-50, 2006.

Z. Chen, J. Yang, S. Li, M. Lv, Y. Shen et al., Invasive lobular carcinoma of the breast : A special histological type compared with invasive ductal carcinoma, PLoS One, vol.12, issue.9, p.182397, 2017.

S. Sasada, G. Yokoyama, H. Takahashi, K. Koike, K. Ikejiri et al., A case of recurrent breast cancer with bone marrow metastasis treated with weekly paclitaxel therapy, Cancer Chemother, vol.35, issue.9, pp.1611-1614, 2008.

S. Takayama, H. Ueno, S. Kawaguchi, F. Asahara, S. Hoshimoto et al., Cancer Chemother, vol.39, issue.1, pp.99-101, 2012.

A. Ardavanis, P. Kountourakis, G. Orphanos, and G. Rigatos, Low-dose capecitabine in breast cancer patients with symptomatic bone marrow infiltration: A case study, Anticancer Res, vol.28, pp.539-581, 2008.

. Cahyanur-r and . Rinaldi-i, Hormonal Treatment for Symptomatic Bone Marrow Metastasis in Breast Cancer Patients. MAEDICA a, J Clin Med, vol.13, issue.3, pp.238-278, 2018.

T. Ota, N. Miyatake, N. Tanaka, Y. Hasegawa, M. Tokunaga et al., Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer, Gynecol Endocrinol, vol.34, issue.4, pp.286-295, 2018.

J. M. Rubins, The role of myelofibrosis in malignant leukoerythroblastosis, Cancer, vol.51, issue.2, pp.308-319, 1983.

R. Costa, R. B. Costa, S. M. Talamantes, I. Helenowski, J. Peterson et al.,

, Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors : palbociclib and ribociclib. The Breast, vol.35, pp.1-7, 2017.

L. Kassem, K. S. Shohdy, S. Lasheen, O. Abdel-rahman, and T. Bachelot,

, Hematological adverse effects in breast cancer patients treated with cyclindependent kinase 4 and 6 inhibitors : a systematic review and meta-analysis, Breast Cancer, vol.25, issue.1, pp.17-27, 2018.

M. P. Goetz, M. Toi, M. Campone, J. Sohn, S. Paluch-shimon et al., MONARCH 3 : Abemaciclib As Initial Therapy for Advanced Breast Cancer, J Clin Oncol, issue.32, p.35, 2017.

B. Laderian and T. Fojo, CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib, Semin Oncol, vol.44, issue.6, pp.395-403, 2017.

W. Sun, P. Dwyer, R. S. Finn, A. Ruiz-garcia, D. Pharm et al., Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Modeling and Simulation Approach, vol.57, pp.1159-1173, 2017.

W. Hu, T. Sung, B. A. Jessen, S. Thibault, M. B. Finkelstein et al.,

, Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies, vol.22, pp.2000-2008, 2016.